| Objective To investigate the application value of ovarian stimulation with HMG as gonadotropin (Gn) in their first in vitro fertilization and embryo transfer (IVF-ET) cycle for patients with normal ovarian function. Methods From August 2014 to April 2018, a total of 147 patients with normal ovarian function who underwent their fisrt IVF-ET cycle in Center of Reproductive Medicine, and whose age was no more than 35 years old and BMI no more than 25 were selected. Of which, 63 patients were treated with the combination of HMG, clomiphene and/or letrozole, set as HMG group. The other 84 cases with traditional GnRHa down-regulation and recombinant follicular stimulating hormone (rFSH) were used for ovarian stimulation in the Reproductive center of 1st Affiliated Hospital of Anhui Medical University, which was set as rFSH group. Oocytes collected, embryo development, clinical outcomes and cost of Gn were compared between the two groups after one year of oocyte retrieval. Results (1) The total dose (2 038.4±505.02 vs 1 717.3±656.16) IU, duration(11.6±2.12 vs 9.67±3.24) days, and total cost (7 555.6±1871.94 vs 526.63±201.22) yuan of Gn in rFSH group were significantly higher than those of the HMG group (P<0.05). The average number of oocytes obtained in HMG group was less than in rFSH group(P<0.05), but there was no significant difference between the two groups in egg maturation rate, fertilization rate, cleavage rate and blastocyst formation rate (P>0.05). (3) There was no significant difference in fresh transplantation pregnancy rate, miscarriage rate, cumulative FET pregnancy rate, miscarriage rate of FET cycle and total live birth/continued pregnancy rate between the two groups (P>0.05). Conclusions For patients with normal ovarian function and first-time IVF-ET, the use of domestic HMG instead of imported rFSH for ovarian stimulation could achieve satisfactory clinical pregnancy rate and live birth rate, and can also reduce treatment costs significantly. |
